Journal Scans
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
IM Ghobrial, M Gertz, B Laplant, J Camoriano, S Hayman, M Lacy, S Chuma, B Harris, R Leduc, M Rourke, SM Ansell, D Deangelo, A Dispenzieri, L Bergsagel, C Reeder, KC Anderson, PG Richardson, SP Treon, TE Witzig
Yes
20100108
2010 Feb 8
J Clin Oncol
Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenstrom Macroglobulinemia
J Clin Oncol. 2010 Feb 8; Epub ahead of print, IM Ghobrial, M Gertz, B Laplant, J Camoriano, S Hayman, M Lacy, S Chuma, B Harris, R Leduc, M Rourke, SM Ansell, D Deangelo, A Dispenzieri, L Bergsagel, C Reeder, KC Anderson, PG Richardson, SP Treon, TE Witzig
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Preclinical studies conducted in lymphoma and multiple myeloma cells have demonstrated that inhibition of mammalian target of rapamycin (mTOR) induces significant antiproliferative activity in malignant B cells. In addition, co-incubation of patient-derived Waldenstrom macroglobulinemia (WM) cells with rapamycin is associated with cytotoxicity and apoptosis. Clinical trials of the rapamycin analog temsirolimus have shown overall response rates (ORRs) of 40% when used for the treatment of B-cell lymphomas....
